Vigabatrin
Metabolic Dysfunction-Associated Steatotic Liver Disease
Washington University School of MedicineSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
130 Active assets in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dapagliflozin Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 | BBB |
Exenatide Fudan University | Phase 4 | BBB |
Metformin Xiqiao Zhou | Phase 4 | BBB |
Empagliflozin Justin Ryder | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Vigabatrin is also rated in:
benign partial epilepsy of infancy with complex partial seizuresDormant
B
Indicative · Phase 4
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →